(Q85472073)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26112388%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

title

Feasibility and utility of re-treatment with (177)Lu-DOTATATE in GEP-NENs relapsed after treatment with (90)Y-DOTATOC (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26112388%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26112388%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26112388%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Lisa Bodei

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26112388%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Stefano Severi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26112388%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Maddalena Sansovini

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26112388%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Annarita Ianniello

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26112388%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Silvia Nicolini

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26112388%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Valentina Di Iorio

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26112388%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Vincenzo D'Errico

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26112388%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Paola Caroli

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26112388%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Manuela Monti

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26112388%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

publication date

26 June 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26112388%20AND%20SRC:MED&resulttype=core&format=json

European Journal of Nuclear Medicine and Molecular Imaging

18 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26112388%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26112388%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26112388%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

page(s)

1955-1963

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26112388%20AND%20SRC:MED&resulttype=core&format=json

Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate.

18 February 2020

cites work

1 reference

12 December 2020

ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary

1 reference

12 December 2020

New advances in peptide receptor radionuclide therapy.

1 reference

12 December 2020

18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors

1 reference

12 December 2020

Prognostic variables in patients with gastrointestinal carcinoid tumours

1 reference

12 December 2020

Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours

1 reference

12 December 2020

111In-pentetreotide scintigraphy: procedure guidelines for tumour imaging.

1 reference

12 December 2020

GEPNETs update: Radionuclide therapy in neuroendocrine tumors

1 reference

12 December 2020

68Ga-DOTA-Tyr3-Octreotide PET in Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and CT

1 reference

12 December 2020

Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE.

1 reference

12 December 2020

The ENETS guidelines: the new TNM classification system

1 reference

12 December 2020

Treatment with the radiolabelled somatostatin analog Lu-DOTATATE for advanced pancreatic neuroendocrine tumors

1 reference

12 December 2020

68Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors

1 reference

12 December 2020

Repeated cycles of peptide receptor radionuclide therapy (PRRT) – Results and side-effects of the radioisotope 90Y-DOTA TATE, 177Lu-DOTA TATE or 90Y/177Lu-DOTA TATE therapy in patients with disseminated NET

1 reference

12 December 2020

Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival

1 reference

12 December 2020

Role of 18FDG PET/CT in patients treated with 177Lu-DOTATATE for advanced differentiated neuroendocrine tumours.

1 reference

12 December 2020

Patient selection for personalized peptide receptor radionuclide therapy using Ga-68 somatostatin receptor PET/CT.

1 reference

12 December 2020

Molecular Imaging Radiotherapy: Theranostics for Personalized Patient Management of Neuroendocrine Tumors (NETs).

1 reference

12 December 2020

Outcome of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced grade 1/2 pancreatic neuroendocrine tumours

1 reference

12 December 2020

Peptide receptor radionuclide therapy for neuroendocrine tumors in Germany: first results of a multi-institutional cancer registry

1 reference

12 December 2020

Neuroendocrine tumors. Peptide receptor radionuclide therapy

1 reference

12 December 2020

Yttrium-labelled peptides for therapy of NET.

1 reference

12 December 2020

177 Lu-Dota-octreotate radionuclide therapy of advanced gastrointestinal neuroendocrine tumors: results from a phase II study

1 reference

12 December 2020

Outcome and toxicity of salvage therapy with 177Lu-octreotate in patients with metastatic gastroenteropancreatic neuroendocrine tumours

1 reference

12 December 2020

Prognostic factors in gastrointestinal endocrine tumors

1 reference

12 December 2020

Recommendations for management of patients with neuroendocrine liver metastases

1 reference

12 December 2020

Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors

1 reference

12 December 2020

Treatment with 177Lu-DOTATOC of patients with relapse of neuroendocrine tumors after treatment with 90Y-DOTATOC.

1 reference

12 December 2020

Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use

1 reference

12 December 2020

Individualized peptide-related-radionuclide-therapy concept using different radiolabelled somatostatin analogs in advanced cancer patients.

1 reference

12 December 2020

D-lysine reduction of indium-111 octreotide and yttrium-90 octreotide renal uptake

1 reference

12 December 2020

Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers

1 reference

12 December 2020

How smart is peptide receptor radionuclide therapy of neuroendocrine tumors especially in the salvage setting? The clinician's perspective.

1 reference

12 December 2020

The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours

1 reference

12 December 2020

Long-term hematotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate

1 reference

12 December 2020

Peptide receptor radionuclide therapy with ¹⁷⁷Lu-DOTATATE: the IEO phase I-II study

1 reference

12 December 2020

Salvage therapy with (177)Lu-octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumors

1 reference

12 December 2020

Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors.

1 reference

12 December 2020

A multianalyte PCR blood test outperforms single analyte ELISAs (chromogranin A, pancreastatin, neurokinin A) for neuroendocrine tumor detection.

1 reference

12 December 2020